Jens G. Lohr
No Rating Available
(Learn About Our Rating System)

Jens G. Lohr, MD, PhD

Languages spoken: English

Dr. Lohr obtained his MD and PhD in Immunology at the Ruprecht-Karls University, Heidelberg, Germany. He conducted postdoctoral research in immunology and subsequently trained in Internal Medicine at UCSF. He completed a Hematology/Oncology fellowship at Dana–Farber Institute (Harvard Medical School), received further training in cancer genomics, and joined Dana Farber and the Broad Institute as an Assistant Professor of Medicine in 2016.

His research interests are in multiple myeloma and cellular therapies, and he leads successful independent translational research programs in these areas. In addition to his responsibilities as CellReGen director, he has also been appointed Director of Immunotherapy research and is an Associate Professor in the Division of Hematology and Hematologic Malignancies.

Specialties

Board Certification

American Board of Internal Medicine (Sub: Medical Oncology)
American Board of Internal Medicine (Sub: Hematology)

Dr. Lohr obtained his MD and PhD in Immunology at the Ruprecht-Karls University, Heidelberg, Germany. He conducted postdoctoral research in immunology and subsequently trained in Internal Medicine at UCSF. He completed a Hematology/Oncology fellowship at Dana–Farber Institute (Harvard Medical School), received further training in cancer genomics, and joined Dana Farber and the Broad Institute as an Assistant Professor of Medicine in 2016.

His research interests are in multiple myeloma and cellular therapies, and he leads successful independent translational research programs in these areas. In addition to his responsibilities as CellReGen director, he has also been appointed Director of Immunotherapy research and is an Associate Professor in the Division of Hematology and Hematologic Malignancies.

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor
Academic Divisions Hematology & Hematologic Malignancies
Board Certification
American Board of Internal Medicine (Sub: Medical Oncology)
American Board of Internal Medicine (Sub: Hematology)

Education history

Professional Medical Medicine - Ruprecht-Karls-University of Heidelberg Faculty of Medicine M.D.
Doctoral Training Immunology - Ruprecht-Karls-University/DKFZ Ph.D.
Residency Internal Medicine: Hematology/Oncology - University Medical Center Freiburg Resident
Other Training Immunology - University of California, San Francisco Postdoctoral Scholar
Residency Internal Medicine - University of California, San Francisco Resident
Certification Clinical Research - University of California, San Francisco Certificate
Certification Translational Research - Dana-Farber Cancer Institute Certificate
Fellowship Hematology/Oncology - Dana-Farber Cancer Institute, Partners CancerCare Clinical Fellow
Fellowship Cancer Biology - Broad Institute of Massachusetts Institute of Technology & Harvard University Research Fellow

Selected Publications

Journal Article

  1. Altevogt P, Hubbe M, Ruppert M, Lohr J, von Hoegen P, Sammar M, Andrew DP, McEvoy L, Humphries MJ, Butcher E (1995). The alpha 4 integrin chain is a ligand for alpha 4 beta 7 and alpha 4 beta 1. The Journal of experimental medicine, 182(2), 345-55.
  2. Zeller Y, Lohr J, Sammar M, Butcher EC, Altevogt (1998). Asp-698 and Asp-811 of the integrin alpha4-subunit are critical for the formation of a functional heterodimer. The Journal of biological chemistry, 273(12), 6786-95.
  3. Lohr J, Knoechel B, Jiang S, Sharpe AH, Abbas A (2003). The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nature immunology, 4(7), 664-9.
  4. Lohr J, Knoechel B, Kahn EC, Abbas A (2004). Role of B7 in T cell tolerance. Journal of immunology (Baltimore, Md., 173(8), 5028-35.
  5. Knoechel B, Lohr J, Kahn E, Abbas A (2005). The link between lymphocyte deficiency and autoimmunity: roles of endogenous T and B lymphocytes in tolerance. Journal of immunology (Baltimore, Md., 175(1), 21-6.
  6. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas A (2005). Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. The Journal of experimental medicine, 202(10), 1375-86.
  7. Knoechel B, Lohr J, Zhu S, Wong L, Hu D, Ausubel L, Abbas A (2006). Functional and molecular comparison of anergic and regulatory T lymphocytes. Journal of immunology (Baltimore, Md., 176(11), 6473-83.
  8. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas A (2006). Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. The Journal of experimental medicine, 203(13), 2785-91.
  9. Barron L, Knoechel B, Lohr J, Abbas A (2008). Cutting edge: contributions of apoptosis and anergy to systemic T cell tolerance. Journal of immunology (Baltimore, Md., 180(5), 2762-6.
  10. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, Saksena G, Stransky N, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Hernández-Lemus E, Schwarz-Cruz y Celis A, Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS, Lander ES, Habermann TM, Cerhan JR, Shipp MA, Getz G, Golub T (2012). Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 109(10), 3879-84.
  11. Lee E, Iskow R, Yang L, Gokcumen O, Haseley P, Luquette LJ 3rd, Lohr JG, Harris CC, Ding L, Wilson RK, Wheeler DA, Gibbs RA, Kucherlapati R, Lee C, Kharchenko PV, Park PJ, Cancer Genome Atlas Research Networ (2012). Landscape of somatic retrotransposition in human cancers. Science (New York, N.Y.), 337(6097), 967-71.
  12. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499(7457), 214-218.
  13. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Multiple Myeloma Research Consortium, Getz G, Golub T (2014). Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer cell, 25(1), 91-101.
  14. Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, Gillespie SM, Fernandez D, Ku M, Wang H, Piccioni F, Silver SJ, Jain M, Pearson D, Kluk MJ, Ott CJ, Shultz LD, Brehm MA, Greiner DL, Gutierrez A, Stegmaier K, Kung AL, Root DE, Bradner JE, Aster JC, Kelliher MA, Bernstein B (2014). An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature genetics, 46(4), 364-70.
  15. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, Nakabayashi M, Lis RT, Lee GS, Li T, Chabot MS, Ly A, Taplin ME, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, Golub TR, Getz G, Boehm JS, Love J (2014). Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature biotechnology, 32(5), 479-84.
  16. Lohr JG, Kim S, Gould J, Knoechel B, Drier Y, Cotton MJ, Gray D, Birrer N, Wong B, Ha G, Zhang CZ, Guo G, Meyerson M, Yee AJ, Boehm JS, Raje N, Golub T (2016). Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Science translational medicine, 8(363), 363ra147.
  17. Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial I (2017). The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell reports, 19(1), 218-224.
  18. Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O'Connor EP, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson (2017). Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature communications, 8(1), 1324.
  19. Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, Yee AJ, O'Donnell EK, Tai YT, Richardson PG, Bianchi G, Laubach JP, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi NC, Anderson KC, Knoechel B, Lohr J (2018). Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia, 32(8), 1838-1841.
  20. Anand P, Guillaumet-Adkins A, Dimitrova V, Yun H, Drier Y, Sotudeh N, Rogers A, Ouseph MM, Nair M, Potdar S, Isenhart R, Kloeber JA, Vijaykumar T, Niu L, Vincent T, Guo G, Frede J, Harris MH, Place AE, Silverman LB, Teachey DT, Lane AA, DeAngelo DJ, Aster JC, Bernstein BE, Lohr JG, Knoechel (2021). Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood, 137(18), 2463-2480.
  21. Hanna GJ, ONeill A, Cutler JM, Flynn M, Vijaykumar T, Clark JR, Wirth LJ, Lorch JH, Park JC, Mito JK, Lohr JG, Kaufman J, Burr NS, Zon LI, Haddad R (2021). A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral oncology, 119, 105366.
  22. Frede J, Anand P, Sotudeh N, Pinto RA, Nair MS, Stuart H, Yee AJ, Vijaykumar T, Waldschmidt JM, Potdar S, Kloeber JA, Kokkalis A, Dimitrova V, Mann M, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr J (2021). Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nature cell biology, 23(11), 1199-1211.
  23. Waldschmidt JM, Kloeber JA, Anand P, Frede J, Kokkalis A, Dimitrova V, Potdar S, Nair MS, Vijaykumar T, Im NG, Guillaumet-Adkins A, Chopra N, Stuart H, Budano L, Sotudeh N, Guo G, Grassberger C, Yee AJ, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr J (2021). Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma. Clinical cancer research, 27(23), 6432-6444.
  24. Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, Bianchi G, Guo G, Potdar S, Seifer C, Nair MS, Kokkalis A, Kloeber JA, Shapiro S, Budano L, Mann M, Friedman R, Lipe B, Campagnaro E, O'Donnell EK, Zhang CZ, Laubach JP, Munshi NC, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr J (2022). Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia, 36(4), 1078-1087.
  25. Stover EH, Oh C, Keskula P, Choudhury AD, Tseng YY, Adalsteinsson VA, Lohr JG, Thorner AR, Ducar M, Kryukov GV, Ha G, Rosenberg M, Freeman SS, Zhang Z, Wu X, Van Allen EM, Takeda DY, Loda M, Wu CL, Taplin ME, Garraway LA, Boehm JS, Huang F (2022). Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. The Prostate, 82(5), 584-597.
  26. Im NG, Guillaumet-Adkins A, Wal M, Rogers AJ, Frede J, Havig CC, Yang J, Anand P, Stegmann SK, Waldschmidt JM, Sotudeh N, Niu L, Voisine J, Schweiger MR, Grassberger C, Lohr JG, Knoechel (2022). Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy. Cancer immunology research, 10(9), 1055-1068.
  27. Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, Muniz-Feliciano L, Laskowski TJ, Liang S, Moyes JS, Nandivada V, Basar R, Kaplan M, Daher M, Liu E, Li Y, Acharya S, Lin P, Shanley M, Rafei H, Marin D, Mielke S, Champlin RE, Shpall EJ, Chen K, Rezvani (2023). Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Science advances, 9(30), eadd6997.
  28. Abbas AK, Lohr J, Knoechel B, Nagabhushanam (2004). T cell tolerance and autoimmunity. Autoimmunity reviews, 3(7-8), 471-5.
  29. Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni (2017). The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clinical cancer research, 23(15), 3980-3993.
  30. Lohr J, Mielke S, Lübbert M, Behringer (2003). Fatal outcome in a patient with metastatic prostate cancer and acquired severe hypogammaglobulinemia with complete absence of mature peripheral blood B-cells. In vivo (Athens, Greece), 17(5), 505-7.
  31. Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni (2017). The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clinical cancer research, 23(15), 3980-3993.
  32. Wiggers CRM, Yüzügüldü B, Tadros NG, Heavican-Foral TB, Cho EY, Eisenbies ZC, Ozdemir M, Kulp SB, Chae YC, Gutierrez A, Lohr JG, Knoechel (2025). Genome-wide CRISPR screen identifies IRF1 and TFAP4 as transcriptional regulators of Galectin-9 in T cell acute lymphoblastic leukemia. Science advances, 11(12), eads8351.
  33. Waldschmidt JM, Sotudeh N, Arora S, Vijaykumar T, Anand P, Stuart H, Frede J, Campbell T, Kaiser SM, Zheng X, Munshi NC, Anderson KC, Einsele H, Yee AJ, Knoechel B, Lohr JG, Raje N (2025). Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma. Blood advances, 9(5), 1132-1136.
  34. Yee AJ, Laubach JP, Campagnaro EL, Lipe BC, Nadeem O, Friedman RS, Cole CE, O'Donnell EK, Bianchi G, Branagan AR, Schlossman RL, Shapiro SJ, Harrington CC, Burke JN, Gammon MT, Lively KJ, Reimonn CA, Andrade DX, Redd R, Lohr JG, Anderson KC, Richardson PG, Raje N (2025). Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. Blood advances, 9(5), 1163-1170.
  35. Hernandez-Lopez P, Vijaykumar T, Anand P, Auclair D, Frede J, Knoechel B, Lohr J (2024). Dual role of signaling pathways in myeloma requires cell type-specific targeting of ligand-receptor interactions. Blood advances, 8(12), 3173-3185.
  36. Wiggers CRM, Cho EY, Ozdemir M, Bamgbose G, Hegel J, Frede J, Warlitz F, Heavican-Foral TB, Pop I, Shraim R, Pölönen P, Koch V, Tran TH, Mullighan CG, Teachey DT, Bledsoe JR, Pikman Y, Harris MH, Place AE, Silverman LB, Lohr JG, Knoechel (2025). Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia. Nature communications, 16(1), 10263.
  37. Frede J, Poller JC, Shi K, Stuart H, Sotudeh N, Havig C, Lim K, Wiggers CRM, Cho EY, Vijaykumar T, Liu J, Waldschmidt JM, Nair MS, Anand P, Dimitrova V, Montanaro A, Yee AJ, Munshi NC, Anderson KC, Martin N, Kaiser SM, Raab MS, Raje NS, Knoechel B, Lohr J (2025). The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma. Leukemia, 39(12), 3004-3014.
  38. Blocka J, Lim K, Stuart H, Frede J, Tadros NG, Wiggers CRM, Hanna GJ, Knoechel B, Lohr J (2025). Cell-free DNA as a complementary marker of therapeutic futility in adenoid cystic carcinoma. Oral oncology, 169, 107688.
  39. Heavican-Foral TB, Korell F, Scarfò I, Wiggers CRM, B AT, Eisenbies Z, Powers F, Hegel J, Liu J, Kulp S, Silva H, Wu G, Letai A, Stegmaier K, Lohr JG, Weinstock DM, Maus MV, Knoechel (2025). Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma. Leukemia, 39(10), 2452-2464.

Review

  1. Herskind C, Fleckenstein K, Lohr J, Li CY, Wenz F, Lohr (2004). [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. Strahlentherapie und Onkologie, 180(4), 187-93.
  2. Herskind C, Fleckenstein K, Lohr J, Li CY, Wenz F, Lohr (2004). [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies]. Strahlentherapie und Onkologie, 180(6), 331-9.
  3. Lohr J, Knoechel B, Nagabhushanam V, Abbas A (2005). T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. Immunological reviews, 204, 116-27.
  4. Lohr J, Knoechel B, Abbas A (2006). Regulatory T cells in the periphery. Immunological reviews, 212, 149-62.
  5. Abbas AK, Lohr J, Knoechel (2007). Balancing autoaggressive and protective T cell responses. Journal of autoimmunity, 28(2-3), 59-61.
  6. Lohr J, Knoechel B, Caretto D, Abbas A (2009). Balance of Th1 and Th17 effector and peripheral regulatory T cells. Microbes and infection, 11(5), 589-93.
  7. Knoechel B, Lohr J (2013). Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes. Journal of autoimmunity, 45, 15-23.
  8. Waldschmidt JM, Anand P, Knoechel B, Lohr J (2018). Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. Seminars in hematology, 55(1), 33-37.
  9. Waldschmidt JM, Vijaykumar T, Knoechel B, Lohr J (2020). Tracking myeloma tumor DNA in peripheral blood. Best practice & research. Clinical haematology, 33(1), 101146.
  10. Holstein SA, Avet-Loiseau H, Hahn T, Ho CM, Lohr JG, Munshi NC, Paiva B, Pasquini MC, Tario JD Jr, Usmani SZ, Wallace PK, Weisel K, McCarthy P (2018). BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biology of blood and marrow transplantation, 24(4), 641-648.
  11. Baysal M, Julian K, Sborov D, Godara A, McClune B, Lohr JG, Fortuna GG, Mohyuddin G (2025). The past, present, and future of myeloma staging and risk prognostication. The oncologist, 30(10),

News & Podcasts

Huntsman Cancer Institute News